Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results / Mudança de tratamento para o aflibercepte no tratamento da Degeneração Macular neovascular Relacionada à Idade: resultados de 30 meses

ABSTRACT Purpose: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. Methods: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. Results: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). Conclusion: Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.(AU)

RESUMO Objetivo: Avaliar, depois de 30 meses, a função visual e as alterações na espessura macular central de pacientes com degeneração macular relacionada à idade sem resposta terapêutica ao ranibizumabe (Lucentis®) que mudaram seu tratamento para o aflibercepte (Eylea®). Métodos: Realizou-se um estudo retrospectivo de pacientes com degeneração macular neovascular relacionada à idade que mudaram o tratamento para o aflibercepte após 6 ou mais injeções intravítreas de ranibizumabe a intervalos de 4-8 semanas. Todos os pacientes mudaram para o aflibercepte intravítreo (2,0 mg) e depois de 3 injeções consecutivas, seguidas de um regime de dosagem pro re nata, foram avaliados após 30 meses de tratamento. A melhor acuidade visual corrigida, o exame biomicroscópico, a pressão intraocular, a fundoscopia e a espessura macular central foram registrados no início do tratamento, antes da transição para o tratamento com aflibercepte intravítreo e aos 6, 12, 18, 24 e 30 meses de tratamento com o aflibercepte intravítreo. Resultados: Satisfizeram aos critérios de inclusão 33 olhos. A mediana da idade dos pacientes foi de 73,57 ± 7,98 anos. Dos pacientes, 21 (61,8%) eram homens e 12 (35,3%) eram mulheres. Antes da transição para o tratamento com o aflibercepte intravítreo, os pacientes receberam em média 16,8 ± 8,8 injeções de ranibizumabe (faixa 6-38).Depois da transição, o número médio de injeções de aflibercepte foi de 9,09 ± 3,94. Não houve diferenças significativas na melhor acuidade visual corrigida depois da mudança para o aflibercepte em qualquer das avaliações. Houve diminuição significativa da espessura macular central aos 6, 12, 18 e 30 meses (respectivamente, p=0,01, p=0,03, p=0,05, p=0,05 e p<0,001). Conclusão: Pacientes com degeneração macular neovascular relacionada à idade que mudaram seu tratamento para o aflibercepte intravítreo devido à falta de resposta ao ranibizumabe intravítreo, tiveram melhora anatômica significativa da retina; mas embora esse estado tenha persistido, não foi observado nenhum ganho funcional significativo.(AU)

Switch to aflibercept in the treatment of neovascular age-related macular degeneration: 30-month results.

PURPOSE: This study was conducted to evaluate visual function and changes in the central macular thickness of patients with unresponsive neovascular age-related macular degeneration who were switched from ranibizumab (Lucentis®) to aflibercept (Eylea®) treatment at 30 months. METHODS: This retrospective study examined patients with neovascular age-related macular degeneration who were switched to aflibercept after ≥6 previous intravitreal ranibizumab injections at 4- to 8-week intervals. All patients were switched to intravitreal aflibercept (2.0 mg) and analyzed after 3 consecutive injections followed by a prore nata dosing regimen and after 30 months of treatment. Best corrected visual acuity, biomicroscopic examination, intraocular pressure, fundus examination, and central macular thickness were recorded at the start of treatment, before the transition to intravitreal aflibercept treatment, and at 6, 12, 18, 24, and 30 months of intravitreal aflibercept treatment. RESULTS: A total of 33 eyes met the inclusion criteria. The median age of the patients was 73.57 ± 7.98 years, and 21 (61.8%) patients were males and 12 (35.3%) were females. Before the transition, the patients received a mean of 16.8 ± 8.8 ranibizumab injections (range 6-38).After the transition to intravitreal aflibercept treatment, the mean number of aflibercept injections was 9.09 ± 3.94. No significant differences were observed in best corrected visual acuity after the aflibercept switch in any of the months. The central macular thickness was significantly decreased at 6, 12, 18, and 30 months (p=0.01, p=0.03, p=0.05, p=0.05, p<0.001, respectively). CONCLUSION: Patients with neovascular age-related macular degeneration who were switched to intravitreal aflibercept treatment due to unresponsiveness to intravitreal ranibizumab exhibited a significant anatomic improvement in the retina, and although this state persisted, there was no significant functional gain.

Thiol/disulfide homeostasis in retinitis pigmentosa patients.

PURPOSE: This research is aimed at determination of total oxidant status, total antioxidant status, serum thiol-disulfide, catalase, albumin, ischemia-modified albumin, and ceruloplasmin in patients suffering from retinitis pigmentosa and drawing a comparison with these parameters determined from healthy controls. METHODS: The study involved 35 patients of retinitis pigmentosa and 33 controls who were healthy individuals of comparable gender and age. Native thiol, total thiol, disulfide concentration, disulfide/native thiol, disulfide/total thiol, native thiol/total thiol ratios, total oxidant status, total antioxidant status, catalase, ceruloplasmin, albumin, and ischemia-modified albumin were determined from peripheral blood samples and comparison was drawn between the measurements of retinitis pigmentosa and controls. RESULTS: The two groups were similar in gender and age distributions. It was found that retinitis pigmentosa group demonstrated greater total oxidant status, ischemia-modified albumin, and disulfide concentrations as compared to controls (p < 0.001). However, total antioxidant status, catalase, native thiol, total thiol, albumin, and ceruloplasmin of the two groups did not show statistically significant difference (p > 0.05). Moreover, disulfide/total thiol and disulfide/native thiol ratios of the retinitis pigmentosa group were significantly greater in comparison to controls (p < 0.05). CONCLUSION: The researchers reached the conclusion that thiol oxidation in retinitis pigmentosa patients caused the dynamic thiol/disulfide homeostasis to shift toward the generation of disulfide. This is a novel research that involves analysis of thiol/disulfide homeostasis in retinitis pigmentosa patients using a novel automated assay. The researchers identified the cause for persistent oxidative stress and damage reported in retinitis pigmentosa patients. Still, future research is required for analysis of progression of antioxidant-oxidant state through various retinitis pigmentosa stages.

Dexamethasone intravitreal implant in the crystalline lens: a case report.

This report describes the therapeutic effects and outcomes of an accidental injection of an intralenticular sustained-release dexamethasone implant (Ozurdex®) in three patients with diabetic macular edema. All three patients underwent accidental injections of sustained-release intravitreal dexamethasone implants into the crystalline lens by the same surgeon. After the accidental injection of Ozurdex® into the crystalline lens, a remarkable reduction in the macular edema and an improvement in visual acuity were observed, suggesting that a positive outcome can be achieved without immediate surgery.

Dexamethasone intravitreal implant in the crystalline lens: a case report / Implante intravítreo de dexametasona nas lentes do cristalino: um relato de caso

ABSTRACT This report describes the therapeutic effects and outcomes of an accidental injection of an intralenticular sustained-release dexamethasone implant (Ozurdex®) in three patients with diabetic macular edema. All three patients underwent accidental injections of sustained-release intravitreal dexamethasone implants into the crystalline lens by the same surgeon. After the accidental injection of Ozurdex® into the crystalline lens, a remarkable reduction in the macular edema and an improvement in visual acuity were observed, suggesting that a positive outcome can be achieved without immediate surgery.

RESUMO Este estudo descreve os efeitos terapêuticos e os resultados de uma injeção acidental de implante intralenticular de dexametasona de liberação sustentada (Ozurdex®) em três pacientes com edema macular diabético. Todos os três pacientes foram submetidos a injeções acidentais de implantes intravítreos de dexametasona de liberação sustentada na lente do cristalino pelo mesmo cirurgião. Após a injeção acidental de Ozurdex® na lente do cristalino, observou-se uma redução notável no edema macular e uma melhora na acuidade visual, sugerindo que um resultado positivo pode ser alcançado sem cirurgia imediata.

Comparison of pain during intravitreal dexamethasone, ranibizumab and aflibercept injection.

BACKGROUND: This study aimed to compare pain scores of patients during intravitreal aflibercept, ranibizumab or dexamethasone implant injection procedures. METHODS: This study included 162 eyes of 162 patients, who received intravitreal ranibizumab, aflibercept or dexamethasone implant injections at our clinic. Following the injection, patients were asked to rate their pain from 0 (no pain) to 10 (worst pain) using a visual analogue pain score survey (VAS). VAS was evaluated according to age, sex, indication for the injection, number of previous intravitreal injections, and lens status in the study eye. RESULTS: The mean VAS in the ranibizumab, aflibercept or dexamethasone implant groups was 3.38 ± 2.31, 3.82 ± 2.46, and 3.61 ± 2.94, respectively. Female patients reported a higher average pain score than male patients (p = 0.02). Also, phakic patients reported a higher average pain score than pseudophakic patients (p = 0.01). Pain did not significantly correlate with indication for the injection, number of injections, and injection drugs (p > 0.05). CONCLUSION: Pain associated with intravitreal injection is generally mild and associated with sex, age, and lens status. There was no significant difference in pain between intravitreal injections of dexamethasone implant, ranibizumab or aflibercept.

Comparison of central corneal thickness measurements with standard ultrasonic pachymetry and optical devices.

BACKGROUND: To compare the repeatability and agreements of central corneal thickness measurements of healthy individuals obtained by Scheimpflug-Placido topographer (Sirius), anterior segment spectral domain optical coherence tomography (Spectralis) (AS-OCT), optical biometry (AL-Scan) and ultrasonic pachymetry. METHODS: Sixty-four eyes of 32 subjects with no ocular or systemic diseases were included in this study. Central corneal thickness measurements performed with Sirius, AS-OCT, optical biometry AL-Scan and ultrasonic pachymetry were compared. Bland-Altman analysis was used to demonstrate agreement between methods. Intra-examiner repeatability was assessed by using intraclass correlation co-efficients (ICCs). RESULTS: Sixty-four eyes of 32 patients were enrolled (25 male and seven female). The mean age was 23.8 years (range 21-28 years). The mean central corneal thickness was 560.8 ± 37.2 µm, 528.8 ± 32.0 µm, 546.4 ± 33.8 µm, 543.4 ± 35.8 µm for the ultrasonic pachymetry, optical biometry AL-Scan, Sirius and AS-OCT values, respectively. The thickest mean central corneal thickness (560.8 ± 37.2 µm) was obtained from ultrasonic pachymetry. The thinnest mean central corneal thickness (528.8 ± 32.0 µm) was obtained from optical biometry AL-Scan. All four modalities of central corneal thickness measurements correlated closely with each other. Intra-examiner repeatability was excellent for all devices with ICCs > 0.90. CONCLUSIONS: In conclusion, although measurements obtained by various methods correlate well, the measurements are not directly interchangeable. Between ultrasonic pachymetry and the three optical instruments tested, significant diferences can be seen. Therefore, the same imaging method should be used in corneal thickness follow-ups.

Intraobserver Repeatability of Corneal and Anterior Segment Parameters Obtained Using a Scheimpflug Camera-Placido Corneal Topography System.

OBJECTIVES: The aim of this study was to assess the intraobserver repeatability of central corneal thickness, peripheral corneal thickness (PCT), keratometry values (steep K, flat K), white-to-white diameter, and anterior chamber depth using the Sirius topography device (Costruzione Strumenti Oftalmici, Florence, Italy) in healthy eyes. METHODS: A Sirius device was used by a single examiner to assess 100 eyes in 50 healthy patients. Two consecutive scans were acquired for each eye. Repeatability was assessed using test-retest variability, the coefficient of variation (COV), and the intraclass correlation coefficient (ICC). RESULTS: Fifty patients (100 eyes) met the inclusion criteria. There were 18 women (36%) and 32 men (64%), with an age range of 23 to 56 years. The mean age was 30.38±8.03 years. A COV of 0.4% or less and an ICC of more than 0.99 (showing excellent repeatability) were achieved for most parameters, with the exception of PCT (at 2.5-mm temporal, superior, inferior, and nasal thickness). CONCLUSION: The anterior segment parameters obtained using the Sirius Scheimpflug camera- Placido corneal topography system were highly repeatable.

Multimodal imaging in a child with severe posterior scleritis.

Objective: Posterior scleritis in a child is a rare condition. High-resolution imaging techniques in the course of posterior scleritis have not been published extensively in literature. The authors reported a case of posterior scleritis in a 12-year-old child to demonstrate multimodal imaging techniques in the course of development and improvement of the disease. Methods: Case report that included fundus photography, spectral domain optical coherence tomography with enhanced depth imaging, blue-peak autofluorescence, multicolor imaging, fluorescein angiography, indocyanine green angiography, and ultrasonography. Results: A twelve-year-old healthy boy presented with ocular pain and mild vision loss. His visual acuity was 20/ 32. There was no sign of inflammation on the ocular surface. There were no cells in the anterior chamber or vitreous. Ultrasonography revealed the diagnosis of posterior scleritis. When he was seen the next day for multimodal imaging techniques, he presented with exudative retinal detachment with visual acuity of 20/ 100. One week after the beginning of the therapy, ocular symptoms, and findings resolved and visual acuity improved to 20/ 20. Conclusion: Multimodal imaging techniques, which are important for the diagnosis of posterior scleritis, before and after the treatment, are presented in this case report.

[Evaluation of smoking cessation services approaches of the patients applying to Hacettepe Adult Hospital]. / Hacettepe Eriskin Hastanesine basvuran hastalarin sigara birakma hizmetleri hakkindaki yaklasimlarinin degerlendirilmesi.

INTRODUCTION: This research was conducted to determine the views and information of the society about smoking cessation services and to find out the smoking status. MATERIALS AND METHODS: This descriptive study was conducted at Hacettepe University Adult Hospital. The questionnaire was conducted to the participants with face to face interview techniques between the dates 3-8 August 2011 and asked about socio-demographic characteristics, smoking status and the views on smoking cessation methods and services. In the analysis, descriptive statistics, chi-square and Fisher's exact chi-square test was used where necessary. p< 0.05 was accepted for statistical significance. RESULTS: The average age of 599 individuals participated to the research was 36.95 ± 12.80 years and 56.6% were male. The participants declared their smoking status that 48.9% do not smoke, 15.9% quit smoking, 35.2% stated as still smoking. Among current smokers 60.2% thought to quit smoking in the last 12 months. Of the participants 42.1% have tried to quit smoking in the past 12 months. 46% percent of smokers and 56.3% non-smokers stated that they are aware of smoking cessation outpatient clinics (p= 0.033). The percentage of awareness of smoking cessation line was 67.8%, and 46.9% are aware of AMATEMs. Same percentages are as 49.5% and 28.4% for the ones who quit smoking. 59.7% of smokers think that nicotine-free preparates and 17.4% think that nicotine preparates is successful; these percentages are 89.7% and 36.7% for non-smokers. CONCLUSION: Tendency to cessation among tobacco users and have awareness about the services that support cessation and believe that the law reduces the harms of tobacco use. However, more interventions are needed to reach those who are at low-income level. Also being a role model to the children in the society and to use attitudes and behaviors in smoking cessation campaigns are thought to be effective.